31 Ene.

Generating Evidence for Patient Access to Medicines and Other Health Technologies: How Much Evidence Is Good Enough?

Localización: Online Organizador: Cel For Pharma Ver programa Añadir a Calendario (ICS) Añadir a Google Calendar

Patients and healthcare systems should optimally benefit from innovative health technologies such as medicines and medtech solutions. But misalignment between HTA bodies/payers and the industry about the interpretation of value and value for money causes delays in market and patient access. There is uncertainty about how much evidence is enough for decision makers to consider a new health technology as a truly beneficial and valuable innovation.

In this e-seminar, Prof. Dr. Lieven Annemans will discuss the issue in depth and provide solutions with specific recommendations for the innovative pharma and medtech industries.

Path Copy Created with Sketch.